Literature DB >> 15109502

Lowering fear-avoidance and enhancing function through exposure in vivo. A multiple baseline study across six patients with back pain.

Katja Boersma1, Steven Linton, Thomas Overmeer, Markus Jansson, Johan Vlaeyen, Jeroen de Jong.   

Abstract

This study investigated the effects of an exposure in vivo treatment for chronic pain patients with high levels of fear and avoidance. The fear-avoidance model offers an enticing explanation of why some back pain patients develop persistent disability, stressing the role of catastrophic interpretations; largely fueled by beliefs and expectations that activity will cause injury and will worsen the pain problem. Recently, an exposure in vivo treatment was developed that aims to enhance function by directly addressing these fears and expectations. The purpose of this study was to describe the short-term, consequent effect of an exposure in vivo treatment. The study employed a multiple baseline design with six patients who were selected based on their high levels of fear and avoidance. The results demonstrated clear decreases in rated fear and avoidance beliefs while function increased substantially. These improvements were observed even though rated pain intensity actually decreased somewhat. Thus, the results replicate and extend the findings of previous studies to a new setting, with other therapists and a new research design. These results, together with the initial studies, provide a basis for pursuing and further developing the exposure technique and to test it in group designs with larger samples.

Entities:  

Mesh:

Year:  2004        PMID: 15109502     DOI: 10.1016/j.pain.2003.03.001

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  31 in total

1.  Return to work after two years of total disability: a case report.

Authors:  Donald R Murphy; Alisson Rosenblum
Journal:  J Occup Rehabil       Date:  2006-06

2.  [Fear Avoidance Beliefs and physical function in elderly individuals with chronic low back pain].

Authors:  H-D Basler; S Quint; U Wolf
Journal:  Schmerz       Date:  2006-06       Impact factor: 1.107

3.  [AMIKA: psychometric evaluation of a photo-based scale for the assessment of fear avoidance beliefs in elderly individuals].

Authors:  S Quint; J Luckmann; U Wolf; H-D Basler
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

4.  Neural circuitry underlying effects of context on human pain-related fear extinction in a renewal paradigm.

Authors:  Adriane Icenhour; Joswin Kattoor; Sven Benson; Armgard Boekstegers; Marc Schlamann; Christian J Merz; Michael Forsting; Sigrid Elsenbruch
Journal:  Hum Brain Mapp       Date:  2015-06-09       Impact factor: 5.038

Review 5.  [Behavioral concepts in the treatment of chronic pain].

Authors:  U Kaiser; P Nilges
Journal:  Schmerz       Date:  2015-04       Impact factor: 1.107

6.  Considerations for late stage acl rehabilitation and return to sport to limit re-injury risk and maximize athletic performance.

Authors:  Daniel P Bien; Thomas J Dubuque
Journal:  Int J Sports Phys Ther       Date:  2015-04

Review 7.  [Exposure therapy for chronic back pain].

Authors:  J A Glombiewski
Journal:  Schmerz       Date:  2018-08       Impact factor: 1.107

Review 8.  Single-case experimental designs: a systematic review of published research and current standards.

Authors:  Justin D Smith
Journal:  Psychol Methods       Date:  2012-07-30

9.  Distinctiveness of psychological obstacles to recovery in low back pain patients in primary care.

Authors:  Nadine E Foster; Elaine Thomas; Annette Bishop; Kate M Dunn; Chris J Main
Journal:  Pain       Date:  2009-12-22       Impact factor: 7.926

10.  Predictive validity of initial fear avoidance beliefs in patients with low back pain receiving physical therapy: is the FABQ a useful screening tool for identifying patients at risk for a poor recovery?

Authors:  Joshua A Cleland; Julie M Fritz; Gerard P Brennan
Journal:  Eur Spine J       Date:  2007-10-10       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.